论文部分内容阅读
AIM To assess the effect of sofosbuvir(SOF) based regimens on glycemic and lipid control.METHODS This is a retrospective analysis of hepatitis C virus(HCV)-infected patients treated and cured with a SOF regimen [SOF/ribavirin/interferon, SOF/simeprevir, or SOF/ledipasvir(LDV) ± ribavirin] from January 2014 to March 2015. Patients with hemoglobin A1C(HbA1C) and lipid panels within six months before and six months after therapy were identified and included in our study. Due to the known hemolytic effect of ribavirin, HbA1C was obtained a minimum of three months post-treatment for the patients treated with a ribavirin regimen. Medical history, demographics, HCV genotype, pre-therapy RNA, and liver biopsies were included in our analysis. The patients who started a new medication or had an adjustment of baseline medical management for hyper-lipidemia or diabetes mellitus(DM) were excluded from our analysis.RESULTS Two hundred and thirty-four patients were reviewed, of which 60 patients met inclusion criteria. Sixty-three point three percent were male, 26.7% were Caucasian, 41.7% were African American and 91.7% were infected with hepatitis C genotype 1. Mean age was 60.6 ± 6.7 years. Thirty-nine patients had HbA1C checked before and after treatment, of which 22 had the diagnosis of DM type 2. HbA1C significantly decreased with treatment of HCV(pretreatment 6.66% ± 0.95% vs posttreatment 6.14% ± 0.65%, P < 0.005). Those treated with SOF/LDV had a lower HbA1C response than those treated with other regimens(0.26% ± 0.53% vs 0.71% ± 0.83%, P = 0.070). Fifty-two patients had pre- and post-treatment lipid panels; there was a significant increase in low-density lipoprotein(LDL) and total cholesterol(TC) after treatment(LDL: 99.5 ± 28.9 mg/dL vs 128.3 ± 34.9 mg/dL, P < 0.001; TC: 171.6 ± 32.5 mg/dL vs 199.7 ± 40.0 mg/dL, P < 0.001). Pretreatment body-mass index(BMI) did not differ from post-treatment BMI(P = 0.684). CONCLUSION Eradication of HCV with a SOF regimen resulted in a significant drop in HbA1C and an increase in LDL and TC post therapy.
AIM To assess the effect of sofosbuvir (SOF) based regimens on glycemic and lipid control. METHODS This is a retrospective analysis of hepatitis C virus (HCV) -infected patients treated and cured with a SOF regimen [SOF / ribavirin / interferon, SOF / simeprevir, or SOF / ledipasvir (LDV) ± ribavirin from January 2014 to March 2015. Patients with hemoglobin A1C (HbA1C) and lipid panels within six months before and six months after therapy were identified and included in our study. Due to the known hemolytic effect of ribavirin, HbA1C was obtained a minimum of three months post-treatment for the patients treated with a ribavirin regimen. Medical history, demographics, HCV genotype, pre-therapy RNA, and liver biopsies were included in our analysis. The patients who started a new medication or had an adjustment of baseline medical management for hyper-lipidemia or diabetes mellitus (DM) were excluded from our analysis. RESULTS One hundred and thirty-four patients were reviewed, of which 60 patients met Sixty-three points three percent were male, 26.7% were Caucasian, 41.7% were African American and 91.7% were infected with hepatitis C genotype 1. Mean age was 60.6 ± 6.7 years. Thirty-nine patients had HbA1C checked before and after treatment, of which 22 had the diagnosis of DM type 2. HbA1C significantly decreased with treatment of HCV (pretreatment 6.66% ± 0.95% vs posttreatment 6.14% ± 0.65%, P <0.005). HbA1C response than those treated with other regimens (0.26% ± 0.53% vs 0.71% ± 0.83%, P = 0.070). Fifty-two patients had pre- and post-treatment lipid panels; there was a significant increase in low-density lipoprotein (LDL: 99.5 ± 28.9 mg / dL vs 128.3 ± 34.9 mg / dL, P <0.001; TC: 171.6 ± 32.5 mg / dL vs 199.7 ± 40.0 mg / dL, P < 0.001). Pretreatment body-mass index (BMI) did not differ from post-treatment BMI (P = 0.684). CONCLUSION Eradication of HCV with a SOF regimen resul ted in a ssignificant drop in HbA1C and an increase in LDL and TC post therapy.